CARA Cara Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CARA

Price (delayed)

$5.045

Market cap

$272.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.59

Enterprise value

$209.91M

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is ...

Highlights
The revenue has surged by 82% year-on-year and by 6% since the previous quarter
CARA's gross profit has soared by 50% YoY
The quick ratio has declined by 33% year-on-year but it has increased by 8% since the previous quarter
Cara Therapeutics's equity has decreased by 30% YoY and by 14% from the previous quarter
The gross margin has declined by 17% year-on-year and by 5% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.caratherapeutics.com
Peers: TRVN ACRX PFE JNJ

Key stats

What are the main financial stats of CARA
Market
Shares outstanding
53.94M
Market cap
$272.14M
Enterprise value
$209.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.71
Price to sales (P/S)
6.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.01
Earnings
Revenue
$41.87M
EBIT
-$85.47M
EBITDA
-$83.8M
Free cash flow
-$78.77M
Per share
EPS
-$1.59
Free cash flow per share
-$1.47
Book value per share
$2.95
Revenue per share
$0.78
TBVPS
$3.4
Balance sheet
Total assets
$182.24M
Total liabilities
$23.46M
Debt
$1.92M
Equity
$158.78M
Working capital
$145.45M
Liquidity
Debt to equity
0.01
Current ratio
7.2
Quick ratio
6.38
Net debt/EBITDA
0.74
Margins
EBITDA margin
-200.2%
Gross margin
82.6%
Net margin
-204.2%
Operating margin
-209.1%
Efficiency
Return on assets
-40.4%
Return on equity
-45.5%
Return on invested capital
-58%
Return on capital employed
-53.8%
Return on sales
-204.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CARA stock price

How has the Cara Therapeutics stock price performed over time
Intraday
2.54%
1 week
-4.81%
1 month
-49.8%
1 year
-59.12%
YTD
-53.03%
QTD
-53.03%

Financial performance

How have Cara Therapeutics's revenue and profit performed over time
Revenue
$41.87M
Gross profit
$34.6M
Operating income
-$87.54M
Net income
-$85.47M
Gross margin
82.6%
Net margin
-204.2%
The revenue has surged by 82% year-on-year and by 6% since the previous quarter
CARA's gross profit has soared by 50% YoY
CARA's net margin is up by 47% year-on-year and by 9% since the previous quarter
Cara Therapeutics's operating margin has increased by 46% YoY and by 8% from the previous quarter

Growth

What is Cara Therapeutics's growth rate over time

Valuation

What is Cara Therapeutics stock price valuation
P/E
N/A
P/B
1.71
P/S
6.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.01
Cara Therapeutics's EPS has increased by 9% YoY and by 4.8% from the previous quarter
The P/B is 63% lower than the 5-year quarterly average of 4.6 and 43% lower than the last 4 quarters average of 3.0
Cara Therapeutics's equity has decreased by 30% YoY and by 14% from the previous quarter
CARA's P/S is 83% below its 5-year quarterly average of 38.2 and 58% below its last 4 quarters average of 15.4
The revenue has surged by 82% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Cara Therapeutics business performance
Cara Therapeutics's ROS has increased by 47% YoY and by 9% from the previous quarter
CARA's return on invested capital is down by 33% year-on-year and by 17% since the previous quarter
Cara Therapeutics's return on equity has decreased by 12% YoY and by 6% QoQ
CARA's ROA is down by 8% YoY and by 3.9% QoQ

Dividends

What is CARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CARA.

Financial health

How did Cara Therapeutics financials performed over time
The quick ratio has declined by 33% year-on-year but it has increased by 8% since the previous quarter
Cara Therapeutics's current ratio has decreased by 27% YoY but it has increased by 9% from the previous quarter
CARA's debt is 99% smaller than its equity
The company's debt to equity has shrunk by 50% YoY
CARA's debt is down by 48% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.